Workshop on new drug treatments for substance use disorders
European Behavioral Pharmacology Society (EPBS) workshop on Novel Pharmacotherapies to Treat Substance Use Disorders: From Basic Science to Societal Implications
This workshop brings together experts from around the world to talk about new and exciting treatments for people struggling with substance use disorders, including how things like cannabinoids and psychedelics might help, while also supporting new researchers in the field.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11000097 on NIH RePORTER |
What this research studies
This workshop aims to gather international experts to discuss innovative pharmacological treatments for substance use disorders (SUDs). Participants will explore both laboratory findings and real-world factors that influence the effectiveness of these treatments. The event will also encourage collaboration among researchers and support the development of new investigators in the field. Topics will include promising interventions such as cannabinoids and psychedelics, focusing on their cellular and molecular mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals affected by substance use disorders who may benefit from novel pharmacological interventions.
Not a fit: Patients who are not affected by substance use disorders or those who do not respond to pharmacological treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments for individuals struggling with substance use disorders.
How similar studies have performed: Previous workshops and conferences have successfully fostered collaboration and innovation in the field of substance use disorder treatments, indicating a positive trend in similar research efforts.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: De Wit, Harriet — University of Chicago
- Study coordinator: De Wit, Harriet
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.